echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Immunology News > Phase III data prove that IL-23 monoantigen TREMFYA can maintain skin removal rate in patients with plaque psoriasis for 5 consecutive years.

    Phase III data prove that IL-23 monoantigen TREMFYA can maintain skin removal rate in patients with plaque psoriasis for 5 consecutive years.

    • Last Update: 2020-10-28
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Johnson and Johnson announced new open label extension data for its Phase III clinical study VOYAGE 1, which showed that after nearly five years of treatment with TREMFYA (guselkumab), adult patients with moderate to severe plaque psoriasis consistently maintained high skin removal rates with no new safety signals.
    week 252 of the
    guselkumab joint treatment, 84% of patients received a Psoriasis Regional Severity Index (PASI) 90 response (a 90% increase in PASI scores compared to the baseline), and 82.4% of patients with an overall assessment (IGA) score of 0 (clear) or 1 (almost clear) (IGA 0/1).
    no new security issues were observed after 264 weeks.
    about TREMFYA (guselkumab) Guselkumab is the first approved monoclonal antibody of all-human-targeted interleukin (IL)-23, which selectively binds to the p19 sub-base of IL-23 and inhibits its interaction with the IL-23 receptor.
    IL-23 is an important cause of inflammatory diseases such as psoriasis.
    photo source: The most common form of psoriasis is plaque-like psoriasis, which usually causes areas of the skin that are thick, red or inflamed to be covered with psoriasis, called plaques.
    about 14 million people in Europe suffer from psoriasis, often resulting in a huge physical and mental burden.
    psoriasis is also associated with a variety of complications, including psoriasis arthritis, cardiovascular disease, metabolic syndrome, chronic obstructive pulmonary disease (COPD) and osteoporosis.
    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.